Hepatitis C genotype 1.
To assess advances in the treatment of genotype 1 (G1 hepatitis C virus), in particular, the development of new interferon (and ribavirin)-free treatment regimes. The treatment of hepatitis C has advanced rapidly over the last 24 months. Newer interferon-containing regimes have been developed with improved tolerability, and interferon-free regimes with outstanding efficacy and improved tolerability have been developed. New treatment regimes for hepatitis C virus have significantly altered the outlook for patients with hepatitis C. New interferon-containing treatment regimes with simeprevir and sofosbuvir, which have improved response rates, have shorter treatment durations and fewer side-effects are becoming available, and interferon-free regimes have been developed. The interferon-free regimes involve multidrug combinations or two-drug combinations and offer the possibility of shorter treatment duration with 8 or 12 weeks. The efficacy of the interferon-free regimes is striking with response rates of well over 90% reported in a wide range of different patient populations. The rapid progress in the treatment of hepatitis C will hopefully result in a cure for most patients, thereby significantly decreasing the morbidity and mortality associated with hepatitis C virus infection.